FDA Priority Review for LEQEMBI SC Injection: Positive but Incremental Step

What happened

Eisai and Biogen announced that the FDA has accepted and granted Priority Review for the Biologics License Application for LEQEMBI IQLIK (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease. This follows the August 2025 approval of the SC maintenance dosing and aims to simplify treatment initiation, potentially broadening patient access. However, the SC starting dose still requires MRI monitoring and does not eliminate the safety and infrastructure hurdles that have constrained Leqembi's ramp. While the news supports the bull case for Biogen, it does not materially alter the near-term revenue trajectory given ongoing MS erosion and the need for sustained rare-disease growth. The stock has already rerated ~23% year-to-date, and the market had largely anticipated this filing given prior SC approvals.

Implication

The Priority Review increases the probability of a faster approval and could accelerate Leqembi adoption if the SC starting dose reduces treatment barriers. However, infrastructure constraints, MRI requirements, and competition from Kisunla remain. Biogen's transition thesis depends on rare-disease and launch products growing ≥25% YoY and offsetting MS erosion. Without clear 2026 guidance for ≥3% revenue growth, the stock lacks a catalyst for multiple expansion above ~17x EPS. At $184, the risk/reward is balanced; attractive entry remains ~$165.

Thesis delta

The news reinforces the bull case but does not change the fundamental uncertainty around Leqembi's ramp and Biogen's ability to stabilize revenue. The existing 'WAIT' rating and $185 base case already incorporate gradual SC adoption. No material shift; the thesis hinges on 2026 guidance and 2-3 more quarters of data.